Itacitinib
As of the edition of 20 October 2026, Itacitinib is a small molecule: in active development; acts on JAK1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Small molecule
- Registered trials
- 54, 22 stopped early
- Disease areas
- Cancer; Blood and lymph; Immune system; Lungs and airways; Skin and connective tissue; Digestive system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route B and 1 company on route A because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Itacitinib.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Companies on route A for this drug
In the product1 company is on route A because of Itacitinib.
See the 1 company on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| JAK1 | Tyrosine-protein kinase JAK1 | P23458 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 2 | 0 | 0 | 0 |
| Phase 1 | 14 | 7 | 1 | 6 |
| Phase 2 | 36 | 13 | 7 | 15 |
| Phase 3 | 2 | 1 | 0 | 1 |
| All trials | 54 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| SCRI Development Innovations | Lead sponsor of trials | 2020 to now |
| Innovent Biologics | Lead sponsor of trials | 2020 to now |
| Incyte | Lead sponsor of trials |